Tumor markers for radiommunodetection of cancer.
One of the potential uses of tumor-associated antigens or tumor markers, the localization of metastatic tumors using radioactive antibodies, has now been demonstrated and confirmed in clinical situations. The next stage of development in radioimmunodetection will be the improvement of techniques and methodologies. The selection of the optimal marker or markers to be used for localization is one area where improvement will be forthcoming. Guidelines for the choice of potential markers and methods for evaluation of potential markers before being clinically tested are presented in this article.
D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D005069:Evaluation Studies as Topic; D006801:Humans; D007106:Immune Sera; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000276:immunology; D011877:Radionuclide Imaging / Q000379:methods*
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D007106:Immune Sera